← Back to patent-cliff list
Fulvestrant
Tier C — Watch / tradeFulvestrant
AstraZeneca
Originator
2002
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ERs
Brand：Faslodex
Indications (approved)：Breast cancer
Regional status
US
Approved
2002-04-25
EU
Approved
2004-03-09
China
Approved
2010-06-04
Japan
Approved
2011-09-26
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Fulvestrant?
Approved indications include: Breast cancer.
When does the Fulvestrant patent expire?
No public expiry year is available for Fulvestrant yet; this page updates once verified.
How do I get a quote for Fulvestrant intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27